Iovance Biotherapeutics, Inc. (IOVA)
8.04
+0.30
(+3.88%)
USD |
NASDAQ |
Nov 06, 16:00
8.03
-0.01
(-0.12%)
After-Hours: 20:00
Iovance Biotherapeutics Total Long Term Debt (Quarterly) : 42.77M for Sept. 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 42.77M |
| June 30, 2026 | 43.33M |
| March 31, 2026 | 44.88M |
| December 31, 2025 | 45.40M |
| September 30, 2025 | 46.21M |
| June 30, 2025 | 46.10M |
| March 31, 2025 | 45.22M |
| December 31, 2024 | 45.36M |
| September 30, 2024 | 67.39M |
| June 30, 2024 | 70.25M |
| March 31, 2024 | 73.29M |
| December 31, 2023 | 68.08M |
| September 30, 2023 | 69.01M |
| June 30, 2023 | 69.84M |
| March 31, 2023 | 70.61M |
| December 31, 2022 | 72.86M |
| September 30, 2022 | 72.94M |
| June 30, 2022 | 74.00M |
| March 31, 2022 | 72.18M |
| December 31, 2021 | 66.47M |
| September 30, 2021 | 65.73M |
| June 30, 2021 | 47.84M |
| March 31, 2021 | 48.08M |
| December 31, 2020 | 45.38M |
| September 30, 2020 | 3.711M |
| Date | Value |
|---|---|
| June 30, 2020 | 2.001M |
| March 31, 2020 | 3.088M |
| December 31, 2019 | 4.248M |
| September 30, 2019 | 6.017M |
| June 30, 2019 | 4.613M |
| March 31, 2019 | 4.38M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| AVITA Medical, Inc. | 47.13M |
| Halozyme Therapeutics, Inc. | 3.250B |
| CareDx, Inc. | 20.32M |
| Merck & Co., Inc. | 49.69B |
| SELLAS Life Sciences Group, Inc. | 0.157M |